The French metagenomic sequencing firm received funding from both historical and new investors, including debt financing from Norgine Ventures.
The team is now conducting additional studies of mNGS in plasma, as well as looking to reduce turnaround time by running the test on a nanopore sequencer.
The company plans to take a tiered approach to assay development, targeting its first test to 10 viruses commonly detected in transplant patients.
The method, presented at the European Congress of Clinical Microbiology and Infectious Diseases, may provide results in hours rather than a week or more.
While the study showed initial promise, further work will be necessary to clarify its performance for various clinical indications.
A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.
The Stanford spinout has launched an infectious disease test that sequences cell-free pathogen DNA to diagnose sepsis in immunocompromised patients.
At IDWeek 2018, several labs reported that they are now using or developing metagenomic NGS tests to diagnose central nervous system infections.
Already, public health organizations in the UK, the Netherlands, and New York state are moving toward implementing NGS for tuberculosis drug susceptibility testing.
The funding will support the further development of Aperiomics' deep metagenomic shotgun sequencing-based test for identifying infectious disease pathogens.